Gracell (GRCL) Long-Term Debt to Capital Ratio

Gracell Biotechnologies - graphic logo of issuer GRCL

Gracell Biotechnologies is protected by exclusive patents for the rapid creation of therapeutic cells in the US and China, operating within the strict frameworks of the FDA and NMPA. This historical price chart demonstrates the asset's dynamics, with the indicator standing at 0.02. The company drives innovation through partnerships with global clinics. A proprietary digital production system ensures a technological leap and cost reductions, creating a powerful competitive barrier.

Long-Term Debt to Equity: Gracell Biotechnologies (GRCL) for 07/04/2022 - 03/03/2024

Analytical breakdowns for Gracell Biotechnologies

- market price and analyst price targets:
Market Price Gracell Bio|GRCL - Price Target Chart
- market capitalization details:
Market Capitalization Gracell Biotechnologies Inc.|GRCL - Enterprise Value
- issuer book value statistics:
Accounting Value per Share Gracell Biotechnologies|GRCL - Company Book Value|Market-to-Book Ratio gracellbio.com|GRCL - Aggregate Company Assets
- debt and solvency information:
Debt to Equity Gracell Biotechnologies|GRCL - Long-Term Debt to Equity|Current Liabilities to Capital gracellbio.com|GRCL - Company Aggregate Debts|Debt to Net Assets Gracell Biotechnologies Inc.|GRCL - Company Long-Term Liabilities|Short-Term Debt Gracell Biotechnologies|Intermediate Coverage Ratio gracellbio.com
- company profitability and valuation multiples indicators:
GRCL - Net Profit
Summary company analysis:GRCL - Gracell Bio
Brand item of Gracell Biotechnologies Ltd

Gracell Biotechnologies dominates the rapid CAR-T therapy creation segment thanks to its FasTCAR platform. This indicator digitizes the cost of scaling such innovations through the long-term debt-to-equity ratio. The metric measures the business's degree of dependence on external borrowings with a term exceeding one year. This allows for an assessment of the balance between financial stability and the risk of underutilizing leverage. By analyzing the long-term debt-to-equity profile, an investor determines the trajectory of the capital structure transformation.

Competing companies

Long-Term Liabilities to Capital Legend Biotech Corp LEGN|Long-Term Debt to Equity Sana Bio (SANA)|Autolus Corp - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital ALLO (Allogene Therapeutics)|RNAC - Long-Term Debt to Equity Ratio|CLLS - Long-Term Debt to Equity|Long-Term Liabilities to Capital Caribou Biosciences Inc.|Instil Bio, Inc (TIL) - Long-Term Debt to Equity|GNTA (Genenta Science) - Long-Term Debt to Equity|Long-Term Debt to Equity Century Tx|Long-Term Liabilities to Capital Jasper Bio JSPR|Long-Term Debt to Capital SNTI|adaptimmune.com (ADAP) - Long-Term Indebtedness to Equity|CERo Therapeutics Holdings - Long-Term Debt to Equity Ratio|Alaunos Therapeutics Inc. (TCRT) - Long-Term Liabilities to Capital|ACHL: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient CRGX (cargo-tx.com)|PSTX: Long-Term Debt to Capital|Long-Term Debt to Equity Ratio 2seventy bio Inc.